10th week of 2009 patent applcation highlights part 50 |
Patent application number | Title | Published |
20090060892 | AGENTS FOR SUPPRESSING HEPATIC FIBROSIS - The present invention relates to hepatic fibrosis-suppressing agents that are suitable for treating or preventing fibrotic liver diseases such as cirrhosis, which comprise as an active ingredient a substance that inhibits the production or accumulation of chondroitin sulfate proteoglycans including chondroitinase ABC and ADAMTS-4; and methods of screening for the agents. | 2009-03-05 |
20090060893 | Methods for enlarging the diameter of a biological conduit in a human subject - The invention provides methods for treating a an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation. | 2009-03-05 |
20090060894 | Treatment to aid in the metabolism of alcohol - Alcohol intoxication is a serious problem. Many individuals are more sensitive to alcohol intoxication and placed at a decided disadvantage in social drinking situations. What is proposed is a way to facilitate alcohol metabolism in individuals who have consumed alcohol by the administration of enzymes to speed the alcohols metabolism. | 2009-03-05 |
20090060895 | Compositions and Methods of Using Chondroitinase ABCI Mutants - The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided. | 2009-03-05 |
20090060896 | Gene repair involving in vivo excision of targeting DNA - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. | 2009-03-05 |
20090060897 | Systems for enlarging the diameter of a biological conduit in a human subject - The invention provides systems for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation. | 2009-03-05 |
20090060898 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response - The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen. | 2009-03-05 |
20090060899 | COMPOSITION OF ORGANIC COMPOUNDS - The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the Aβ-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the A | 2009-03-05 |
20090060900 | Methods for Screening Compounds That Modulate Lipid Metabolism - Drug screening assays useful in the discovery of pharmaceutically active compounds for use in the treatment of diseases involving abnormal lipid metabolism including diabetic neuropathy are taught. In particular, the control region of delta-5-desaturase gene is taught as a target for the drug screening methods, which serve to identify nucleotides, proteins, compounds and/or other pharmacological agents, which modulate the activity of desaturase enzymes or regulate the level of expression of the desaturase genes. Cell-based and cell lysate assays are taught for detecting components that interact with the desaturase enzymes and modify fatty acid profiles. In addition, cell-based and cell lysate assays are used to identify functional and regulatory elements controlling expression of the desaturase genes as well as to screen for components that modulate the transcriptional activity of the desaturase genes. Also taught is the gene for rat delta-5-desaturase. | 2009-03-05 |
20090060901 | DETOXIFICATION METHOD - The present invention provides a protein toxoid for use in a method of treating the human or animal body by therapy, wherein all cysteine residues in said protein toxoid which are free under reversibly denaturing conditions have been alkylated. | 2009-03-05 |
20090060902 | Methods and compositions for regulating T cell subsets by modulating transcription factor activity - Methods for modulating production of a T helper type 2 (Th | 2009-03-05 |
20090060903 | Pharmaceutical Compositions Comprising an Anti-Teratogenic Compound and Applications of the Same - Pharmaceutical compositions comprising anti-teratogenic agents are disclosed. Additionally, pharmaceutical compositions comprising anti-neoplastic agents and anti-teratogenic agents are disclosed. Methods of assessing the teratogenicity of a compound are disclosed. The present invention further comprises applications of the aforementioned compositions and methods. | 2009-03-05 |
20090060904 | Vegetarian Protein A Preparation and Methods Thereof - The invention relates to methods of producing Protein A without contamination of the Protein A by animal products. The invention also relates to a vegetarian fermentation media in which | 2009-03-05 |
20090060905 | Use of 15-Lipoxygenase Inhibitors for Treating Obesity - The invention concerns the treatment of obesity, in particular abdominal visceral obesity. More specifically, the invention concerns the use of selective 15-lipoxygenase (LO) inhibitors for preparing medicines useful in the treatment of obesity, or at least abdominal visceral obesity, and/or its consequences. | 2009-03-05 |
20090060906 | Anti-IL-13 antibody formulations and uses thereof - Formulations suitable for treatment of disorders associated with undesirable expression or activity of IL-13 are provided. | 2009-03-05 |
20090060907 | Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3 - Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells. | 2009-03-05 |
20090060908 | Monoclonal Antibodies Against Prostate Specific Membrane Antigen (PSMA) Lacking in Fucosyl Residues - The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided. | 2009-03-05 |
20090060909 | ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY - The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. | 2009-03-05 |
20090060910 | COVALENT DIABODIES AND USES THEREOF - The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule. | 2009-03-05 |
20090060911 | ENHANCEMENT OF ANTIBODY-MEDIATED IMMUNE RESPONSES - The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcγRIIB-mediated activity. In particular disrupting SHIP activation by FcγRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region that results in binding of the antibody to FcγRIIB with reduced affinity. A variety of transgenic mouse models demonstrate that the inhibiting FcγRIIB molecule is a potent regulator of cytotoxicity in vivo. | 2009-03-05 |
20090060912 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE - Compounds having formula I are provided where the variables have the values described herein. | 2009-03-05 |
20090060913 | COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES - The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. | 2009-03-05 |
20090060914 | DEIMMUNIZED MONOCLONAL ANTIBODIES FOR PROTECTION AGAINST HIV EXPOSURE AND TREATMENT OF HIV INFECTION - This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG | 2009-03-05 |
20090060915 | POLYPEPTIDE, VACCINE AND USE THEREOF - The present invention relates to prophylactic or therapeutic treatments for hindering blood vessel formation (for example, angiogenesis) for example for hindering tumour growth. In particular, the invention relates to a vaccine or medicament comprising a whole angiomotin molecule or a fragment thereof which may be used to generate immune responses to angiomotin. The invention also provides antibodies specific for a whole angiomotin molecule or a fragment thereof for use in prophylactic or therapeutic treatments. | 2009-03-05 |
20090060916 | Ligands that bind IL-4 and/or IL-13 - Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described. | 2009-03-05 |
20090060917 | Carbamate Stereoisomer - The compound of formula (I) | 2009-03-05 |
20090060918 | Method of treating or preventing an IL-1 related disease or condition - Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide is provided. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 2009-03-05 |
20090060919 | BINDING MEMBERS FOR IgE MOLECULES - This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma. | 2009-03-05 |
20090060920 | DESACYL GHRELIN ANTIBODIES AND THERAPEUTIC USES THEREOF - A neutralizing epitope is identified within amino acids 1-3 of desacyl ghrelin. Antibodies that bind this epitope fall within the scope of the invention and can be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies, or antigen-binding fragments thereof. The antibodies of the invention are useful for the treatment or prevention of obesity and related disorders including, for example, Type II non-insulin dependent diabetes mellitus (NIDDM), Prader-Willi syndrome, eating disorders, hyperphagia, and impaired satiety. Additionally, such antibodies can be useful for the treatment or prevention of other disorders, including anxiety, gastric motility disorders (including e.g., irritable bowel syndrome and functional dyspepsia), insulin resistance syndrome, metabolic syndrome, dyslipidemia, atherosclerosis, hypertension, hyperandrogenism, polycystic ovarian syndrome, cancer, and cardiovascular disorders by administering a therapeutically effective amount of an anti-desacyl ghrelin monoclonal antibody of the invention. | 2009-03-05 |
20090060921 | GLYCAN-OPTIMIZED ANTI-CD20 ANTIBODIES - Glycan-optimized monoclonal antibodies that specifically bind CD20 antigen and which have improved effector function are provided. The anti-CD20 antibodies of the invention have a glycosylation pattern that results in an antibody composition having predominately the G0 glycoform, and thus comprise N-glycans that lack fucose (i.e., afucosylated) and galactose residues attached thereto. In some embodiments, these anti-CD20 antibodies comprise the light chain and heavy chain sequences of the rituximab anti-CD20 antibody, and thus represent afucosylated rituximab. Methods for producing these glycan-optimized anti-CD20 antibodies are also provided. | 2009-03-05 |
20090060922 | Acetamide Stereoisomer - The compound of formula (I) | 2009-03-05 |
20090060923 | Method of treating or preventing an IL-1 related disease or condition - Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide is provided. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 2009-03-05 |
20090060924 | ANTI-SCLEROSTIN ANTIBODIES - Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject. | 2009-03-05 |
20090060925 | Rage Fusion Proteins and Methods of Use - Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies. | 2009-03-05 |
20090060926 | MEDICINE FOR TREATMENT OF CARCINOMA - A medicine for treatment of a carcinoma which can be supplied to the carcinoma via the circulatory system, contains two active components coupled to one another. The first active component is formed of at least one coupling molecule that specifically tethers to a target molecule formed by the cancer tissue. The second active component is formed of at least one signal molecule typical to inflammation, or of at least originating molecule encoding such a signal molecule. | 2009-03-05 |
20090060927 | Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination - The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity. | 2009-03-05 |
20090060928 | Topical Toll Like Receptor Ligands as Vaccine Adjuvants - The present invention provides a method for increasing immunological response to a vaccine, comprising administering the vaccine subcutaneously to a patient in need thereof; anti administering a topical composition containing an amount of a toll like receptor ligand effective to increase immune response of the patient to the vaccine. | 2009-03-05 |
20090060929 | Transfection complexes - The invention provides a peptide having at least 3 amino acids comprising an amino acid sequence selected from | 2009-03-05 |
20090060930 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. | 2009-03-05 |
20090060931 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING OVARIAN CANCER - The invention relates to therapeutic and prophylactic treatment of ovarian cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of an ovarian tissue cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof in immunotherapeutic methods of treatment. Said immunogenic polypeptides are provided by the zona pellucida (ZP) glycoproteins. ZP glycoproteins and fragments thereof that can induce a CD8 | 2009-03-05 |
20090060932 | Groups Of Borrelia Burgdorferi And Borrelia Afzelii That Cause Lyme Disease In Humans - The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causing | 2009-03-05 |
20090060933 | PROTEASES PRODUCING AN ALTERED IMMUNOGENIC RESPONSE AND METHODS OF MAKING AND USING THE SAME - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins. | 2009-03-05 |
20090060934 | S. AGALACTIAE ANTIGENS I & II - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 2009-03-05 |
20090060935 | AMEBIASIS VACCINE - An isolated protein fragment containing an epitope which is specific for | 2009-03-05 |
20090060936 | Ii-Key/Her-2/neu hybrid cancer vaccine - Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK (SEQ ID NO: 2) residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide. | 2009-03-05 |
20090060937 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF - Oligonucleotides containing the non-palindromic sequence motif:
| 2009-03-05 |
20090060938 | Polyvalent Conjugate Vaccine for Cancer - This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Le | 2009-03-05 |
20090060939 | COMPOSITIONS AND METHODS FOR TREATING ALLERGIES, AUTO-IMMUNE DISEASES, AND IMPROVING SKIN CONDITION BY GANODERMA LUCIDUM (REISHI) POLYSACCHARIDES - A method for treating an allergy by providing a pharmaceutical composition containing at least | 2009-03-05 |
20090060940 | Compositions and methods for treating psoriasis by ganoderma lucidum (Reishi) polysaccharides - A method for treating psoriasis by providing a pharmaceutical composition containing at least | 2009-03-05 |
20090060941 | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols - A composition for treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is disclosed. A method of treating a subject suffering from insulin-dependent diabetes by administering a composition that includes at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is similarly provided. The administration of a composition containing an effective dose of at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol for the treatment of obesity is likewise provided. | 2009-03-05 |
20090060942 | Detoxification Composition and Method of Detoxifying the Body - The present invention provides a detoxification composition including alginate, and ulva rigida extract. The present invention further provides a method of detoxifying and cleansing the human body of mutagens, and toxins; reducing cholesterol levels; and preventing or protecting against colon cancer. | 2009-03-05 |
20090060943 | Syndrome X Composition and Method of Lowering Blood Pressure and Glycemic Index - The present invention provides a composition including alginate, seaweed fiber, piperine and potassium citrate for lowering blood pressure, lowering glycemic index, and alleviating conditions associated with Syndrome X. The present invention also provides a method of lowering blood pressure, lowering glycemic index and alleviating conditions associated with Syndrome X. The present invention further provides a method of preventing or protecting against heart disease, diabetes, and hypertension. | 2009-03-05 |
20090060944 | Enhancer Of The Effect Of Adrenocorticoid,Comprising Gum Arabic - This invention provides an enhancer of the effect of adrenocorticoid on nephritis without enhancement of the undesirable side-effects of the said adrenocorticoid, comprising the water-soluble gum obtained from the stem and/or branch of | 2009-03-05 |
20090060945 | Integration of meningococcal conjugate vaccination - Conjugated meningococcal capsular saccharides will be introduced into immunisation schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. It has been found that diphtheria toxoid and its derivatives (such as CRM197) can safely be used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunising a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunised with a diphtheria toxoid (or derivative thereof). | 2009-03-05 |
20090060946 | Activation of antigen-specific T cells by virus/antigen-treated dendritic cells - The present invention relates to a T cell activating agent containing dendritic cells (DC) treated with virus-treated antigen and/or dendritic cells treated separately with virus and antigen, which may be used as a vaccine to stimulate an immune response in a patient obtainable by the activation of antigen-specific T cells (TC) in vivo, to a composition containing activated TC which are activated by the T cell activating agent in vitro, to a pharmaceutical composition containing the T cell activating agent and/or the composition as well as to methods for their production. | 2009-03-05 |
20090060947 | Immunological compositions - The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV). | 2009-03-05 |
20090060948 | CATIONIC LIPID-MEDIATED ENHANCEMENT OF NUCLEIC ACID IMMUNIZATION OF CATS - The present invention relates to a method to introduce a nucleic acid molecule into a fetid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cationic lipid complex to elicit and/or enhance an immune response. In one embodiment, this method enhances the immune response in a fetid compared to a method in which a naked DNA vaccine is administered to a felid. Also provided is a method to deliver a nucleic acid to a felid. This method comprises parenterally administering to the fetid a composition that includes a nucleic acid molecule complexed with a cationic lipid. | 2009-03-05 |
20090060949 | Flu vaccines and methods of use thereof - This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection. | 2009-03-05 |
20090060950 | Method for Producing Viral Vaccines - The present invention provides a method for the manufacture of a preparation comprising virus antigens comprising a) inoculation of cells with infectious virus in a fluid,
| 2009-03-05 |
20090060951 | DNA VACCINE FOR KOI HERPES VIRUS (KHV) DISEASE - The present invention provides a DNA vaccine for carps for inducing protective immunity against Koi herpesvirus (KHV). The DNA vaccine comprises a DNA comprising a nucleotide sequence encoding an immunogenic polypeptide against Koi herpesvirus (KHV) of carps, or an expression vector comprising the DNA as an active ingredient. | 2009-03-05 |
20090060952 | PRODUCTION OF THE LIPIDATED FORM OF THE PEPTIDOGLYCAN-ASSOCIATED LIPROPROTEINS OF GRAM-NEGATIVE BACTERIA - The expression of the lipidated form of the peptidoglycan-associated protein (PAL) of gram-negative bacteria is achieved through the use of a plasmid containing a tightly regulated promoter. A bacterial host cell is transformed, transduced or transfected with such a plasmid. The host cell is then cultured under conditions such that the lipidated recombinant PAL is expressed. The lipidated recombinant PAL is included in an antigenic composition administered to a mammalian host to immunize against a gram-negative bacterium. | 2009-03-05 |
20090060953 | Methods for using tetanus toxin for beneficial purposes in animals (mammals) - Methods of using tetanus toxin to modulate or control neural functions or nonneural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are provided. Pharmaceutical formulations to modulate neural functions or non-neural cellular activities of an animal at selected sites in animals, particularly in mammals, and more particularly in humans are also provided. Uses of tetanus toxin in preparation of medicaments for methods of treating clinical disorders or symptoms of animals, particularly mammals and more particularly humans are also provided. | 2009-03-05 |
20090060954 | Recombinant BCG Vaccine - A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which the third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine. | 2009-03-05 |
20090060955 | Drug delivery vehicle that mimics viral properties - A drug delivery vehicle for targeted delivery of a drug mimics viral properties of size, capsid-like protein capsule, cell-specific entry, toxin release, destruction of infected cells, and migration to neighboring cells. This vehicle, termed a virogel, contains a hydrophobic polymeric core, a hydrophilic inner shell, a hydrophilic outer shell, and a ligand. An illustrative drug-loaded virogel includes poly(L-histidine-co-phenylalanine) as the core, doxorubicin loaded in the core, polyethylene glycol as the inner shell, bovine serum albumin as the outer shell, and folic acid as the ligand. | 2009-03-05 |
20090060956 | AGENT FOR REDUCING THE USEABLE CALORIE CONTENT OF FOOD AND FOR THERAPEUTIC REDUCTION OF WEIGHT, IN PARTICULAR FOR USE IN THE CASE OF ADIPOSITY (OBESITY) - An agent for reducing the useable calorie content of food is described which contains a compound effecting the dehydrogenation of fructose to 5-keto-D-fructose. In addition, a combination agent is described which also contains a compound that converts glucose to fructose. These agents can be used in particular in the therapy of adiposity (obesity). | 2009-03-05 |
20090060957 | Oral compositions - A multi-phase oral composition, wherein at least one phase has a filling viscosity from about 1.5 to about 5.0 Pa·s at a shear rate of 1000/sec and an after-filling viscosity from about 160 to about 190 Pa·s at a shear rate of 4/sec, and wherein the phases form a visual appearance selected from the group consisting of a pattern, alternating bands, at least one coil, at least one character, and combinations thereof. | 2009-03-05 |
20090060958 | ORAL CARE STRIP OR TAPE AND METHODS OF USE AND MANUFACTURE THEREOF - This invention relates to oral care composition, methods of use and methods of manufacture thereof in the form of a toothtape that can be used to brush or clean teeth and the oral cavity. Particularly, the invention relates to a non-traditional dentifrice that comes in the form of a tape that can, for example, adhere to the oral cavity and particularly the teeth and be dispensed for single use. | 2009-03-05 |
20090060959 | HYDROUS POWDERY COSMETIC PREPARATION - A water-containing powdery cosmetic preparation comprises (a) hydrophobic particles having a surface area of at least 80 m | 2009-03-05 |
20090060960 | Preparation containing barium sulfate - The invention relates to a preparation containing barium sulfate, a method for the production thereof, and the use thereof. | 2009-03-05 |
20090060961 | Spongelike Structure and Powder, As Well As Process for Producing the Same - An object of the present invention is to provide a spongelike structure or a powder having fibers three-dimensionally arranged therein with high dispersibility, whose apparent density can be designed depending on the purpose or utility, as well as a process producing them. A fiber dispersion in which fibers having a number mean diameter in a predetermined range are dispersed in a dispersion medium, and this fiber dispersion is dried to remove the dispersion medium, thereby, a spongelike structure and a powder are produced. | 2009-03-05 |
20090060962 | COSMETIC USE OF BIFIDOBACTERIUM SPECIES LYSATE FOR THE TREATMENT OF DRYNESS - Cosmetic use of an effective amount of a lysate of at least one microorganism of the genus | 2009-03-05 |
20090060963 | Wearing Article Capable of Promoting Human Health - A wearing article includes an article element and a fastening mechanism. The article element includes at least one pack unit that has a fabric housing and a flexible pad body fitted into the fabric housing and including a thin elastic matrix of an elastic material and a plurality of functional particles dispersed in the matrix and capable of providing at least one of the functions consisting of emitting far-infrared rays, emitting negative ions, and destroying bacteria. The fastening mechanism is secured to the pack unit so as to permit wearing of the pack unit by the human body and abutment of the fabric housing against the human body. | 2009-03-05 |
20090060964 | Animal repellant and associated dispenser - A dispenser for an animal repellant including: a housing, wherein the housing includes a chamber for containing a spool; a spool, wherein the spool is associated with the chamber of the housing, and wherein the spool is associated with an animal repellant; and wherein the animal repellant includes a substrate, wherein the substrate is associated with an agent wherein the agent includes an animal repellant. | 2009-03-05 |
20090060965 | Water Dispersible Formulation for Delivery of Biocontrol Fungi to Reduce Aflatoxin - A formulation containing conidia of non-toxigenic strains of fungi is a useful biocontrol agent for preventing toxin contamination in agricultural commodities, especially those for human and animal consumption such as peanuts, corn, cotton and tree nuts. The formulation of the invention is a water dispersible granule formulation suitable for spraying and includes non-toxigenic and/or non-aflatoxigenic | 2009-03-05 |
20090060966 | Pesticidal composition - A pesticidal composition including a microcapsule in which an oil containing a pesticidal active ingredient and an organic solvent is covered with a wall material made of a thermosetting resin, a sorbitan fatty acid ester, a thickener, and water is provided. The pesticidal composition has elution performance suited for an applied situation without the need of changing the design of the microcapsule itself As the thermosetting resin, a polyurethane resin or a polyurea resin is preferred. As the pesticidal active ingredient, an insect growth regulating active ingredient such as 4-phenoxyphenyl2-(2-pyridyloxy)propyl ether is recited. | 2009-03-05 |
20090060967 | Antimicrobial fiber and method for producing the same thereof - An object of the present invention is to provide an antimicrobial fiber having a diameter of approximately 10 to 30 μm that is superior in surface smoothness, transparency, and others, and a method for producing the same thereof. Provided is an antimicrobial fiber, comprising a transparent resin, an antimicrobial glass, and inorganic particles as a dispersant of the antimicrobial glass, wherein a diameter of the antimicrobial fiber is in the range of 10 to 30 μm, an average particle size of the antimicrobial glass is in the range of 0.1 to 10 μm, an addition quantity of the antimicrobial glass is in the range of 0.1 to 10% by weight with respect to the total weight, an average particle size of the inorganic particles is in the range of 1 to 15 μm, and an addition quantity of the inorganic particles is in the range of 0.1 to 50 parts by weight with respect to 100 parts by weight of the addition quantity of the antimicrobial glass. | 2009-03-05 |
20090060968 | INHIBITORS OF PHOSPHATASES - The present invention relates to compounds that inhibit phosphatases, compositions thereof, and methods of using those compounds and compositions for treating diseases. | 2009-03-05 |
20090060969 | Porous biodegradable polymeric materials for cell transplantation - Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted matrix without damage to the cells or patient. The introduced cells attach to the connective tissue within the matrix and are fed by the blood vessels. The preferred material for forming the matrix or support structure is a biocompatible synthetic polymer which degrades in a controlled manner by hydrolysis into harmless metabolites, for example, polyglycolic acid, polylactic acid, polyorthoester, polyanhydride, or copolymers thereof. The rate of tissue ingrowth increases as the porosity and/or the pore size of the implanted devices increases. The time required for the tissue to fill the device depends on the polymer crystallinity and is less for amorphous polymers versus semicrystalline polymers. The vascularity of the advancing tissue is consistent with time and independent of the biomaterial composition and morphology. | 2009-03-05 |
20090060970 | Compositions and methods of administering paclitaxel with other drugs using medical devices - Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs. | 2009-03-05 |
20090060971 | METHODS OF TREATING A TRAUMA OR DISORDER OF THE KNEE JOINT BY LOCAL ADMINISTRATION AND SUSTAINED-DELIVERY OF A BIOLOGICAL AGENT - Methods and apparatus of providing a subject with post-operative, sustained-release of a biological agent within a synovial joint is disclosed. These methods involve securing a depot containing the biological agent to a ligament, tendon, muscle within the joint to provide sustained-release of the agent while allowing for normal joint articulation. This methodology may be utilized to provide for sustained-release of a biological agent useful in treating various traumas and disorders of the joint. Such biological agents include antagonists of inflammation-related proteins, such as TNF-α, IL-1β, IL-6, IL-8, NF-κB, High Mobility Group Box 1 (HMG-B1), IL-2, IL-15 and steroidal and non-steroidal anti-inflammatories. Other biological agents include anti-inflammatory cytokines such as IL-10, IL-4, IL-13, and TGF-β. The biological agents also include osteogenic and cartilage producing growth factors such as, but not limited to, BMP-2, BMP-4, BMP-6, BMP-7, BMP-8, and MIA CD-RAP. Finally, the biological agents include siRNA and/or therapeutic antibodies. | 2009-03-05 |
20090060972 | DEVICE AND METHOD FOR CELL GRAFTING - A device for cell grafting is disclosed. The device comprises a compartment enclosed by a semipermeable envelope made at least in part of nonwoven polymer fibers, and at least one inlet port formed in the envelope. The inlet port(s) are accessible from the exterior of the envelope and configured for establishing fluid communication with the compartment. | 2009-03-05 |
20090060973 | COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS - Medical implants are provided which release a fluoropyrimidine or an analog thereof, thereby inhibiting or reducing the incidence of infection associated with the implant. | 2009-03-05 |
20090060974 | METHODS OF ARTHROSCOPIC OSTEOCHONDRAL RESURFACING - Methods of arthroscopic resurfacing of anatomical tissue utilizing a biological component strengthened with glue or similar material. The biological component is selected from the group consisting of blood, blood components, PRP, bone marrow aspirate (BMA) and autologous conditioned plasma (ACP). The biological component/glue composition may be inserted (by injection and/or by employing a biologic resurfacing mold, for example) into, or in the vicinity of, the anatomical tissue. Upon insertion within, or contact with, the anatomical tissue, the biological component/glue composition is designed to coagulate and solidify (or partially solidify) within minutes, to advance healing or tissue growth of the anatomical tissue. The biological component/glue composition may optionally comprise components such as growth factors, antiseptic chemicals and/or antibiotics and/or electrolytes, or hormones or site-specific hybrid proteins, among others. | 2009-03-05 |
20090060975 | CONTAINMENT SYSTEM FOR DELIVERY OF BIOLOGICAL PRODUCTS AND METHOD OF SURGERY - Methods and systems for delivering biological products such as bone marrow aspirate (BMA) to different surgical sites during surgery (for example, arthroscopic surgery). The biological product is encapsulated or contained within a containment system comprising a carrier such as collagen carrier. The containment system may be formed of water soluble polymers, either natural, synthetic or semisynthetic, provided into films that may be made or molded into various shapes and sizes, and that may be manipulated to confer specific properties (such as solubility or degradation rates according to a specific environment, for example) of such films. The water soluble films may be processed into capsules, packets or other containers. | 2009-03-05 |
20090060976 | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects - Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and defects resulting from degenerative diseases such as osteochondritis dessicans. | 2009-03-05 |
20090060977 | DEVICES, SYSTEMS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER CONDITIONS - Devices, systems and methods for compressing, cutting, incising, reconfiguring, remodeling, attaching, repositioning, supporting, dislocating or altering the composition of tissues or anatomical structures to alter their positional or force relationship to other tissues or anatomical structures. In some applications, the invention may be used to used to improve patency or fluid flow through a body lumen or cavity (e.g., to limit constriction of the urethra by an enlarged prostate gland). | 2009-03-05 |
20090060978 | RESORBABLE BARRIER MICRO-MEMBRANES FOR ATTENUATION OF SCAR TISSUE DURING HEALING - Resorbable lactide polymer micro-membranes are disclosed. The micro-membranes are constructed of polylactide resorbable polymers, which are engineered to be absorbed into the body relatively slowly over time in order to reduce potential negative side effects. The membranes are formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about O.300 mm. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be preshaped with relatively thick portions, and can be stored in sterile packages. | 2009-03-05 |
20090060979 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS - The present invention relates to biodegradable polymers (e.g., polyesters and polyester amides) derived from functionalized biologically active compounds that can provide site specific delivery of bioactive compounds upon biodegradation in a controlled manner. | 2009-03-05 |
20090060980 | GLYCAN BINDING PROTEINS AS THERAPEUTIC TARGETS FOR RETINAL DISORDERS AND TREATMENT METHODS BASED THEREON - Disclosed are novel methods of treatment for retinal diseases and conditions including age-related macular degeneration, genetic-based retinal degenerations and retinal detachment. A novel glycan binding protein thought to be a cell surface receptor has been discovered in the retina. The retinal glycan binding receptor is shown to play an important role in promoting assembly of outer segment (OS) membranes by the photoreceptor cells of the eye, a process that is essential for vision. Based on the finding that certain sugars can bind with very high affinity to the retinal glycan receptor and stimulate its function, the invention provides novel therapeutic agents for treatment of retinal diseases that are multivalent N-linked glycans. Preferred pharmaceutical compositions in accordance with the present invention comprise active agents having the general formula: (Gal-GlcNAc) | 2009-03-05 |
20090060981 | Contact lens based bioactive agent delivery system - A bioactive agent delivery system comprising an optically transparent contact lens having dispersed therein (1) an ophthalmically bioactive agent capable of diffusion through the contact lens and into the post-lens tear film when placed on the eye and (2) associated with the bioactive agent, an ophthalmically compatible polymeric surfactant in an amount sufficient to slow the rate of migration of the bioactive agent through the contact lens. | 2009-03-05 |
20090060982 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 2009-03-05 |
20090060983 | Method And Composition For Making An Orally Disintegrating Dosage Form - The present invention relates to a process for making orally disintegrating dosage forms and means for packaging such dosage forms. | 2009-03-05 |
20090060984 | ANIONIC SURFACTANTS LETHAL TO GRAM-POSITIVE BACTERIA - Disclosed are surfactant compounds and compositions that are antimicrobial. Also provided are polymeric compositions incorporating the surfactant compounds. The polymeric compositions may be used to form antibacterial coatings on surfaces. | 2009-03-05 |
20090060985 | PROCESS FOR THE PREPARATION OF PLANT EXTRACTS FOR TREATING SKIN DISORDERS AND ENHANCING HEALING OF WOUNDS - The present invention provides a process for the preparation of | 2009-03-05 |
20090060986 | Transdermal delivery systems - Disclosed are bupivacaine transdermal delivery systems, and related methods. | 2009-03-05 |
20090060987 | DEVICES, SYSTEMS AND METHODS FOR IMPROVING MEMORY AND/OR COGNITIVE FUNCTION THROUGH BRAIN DELIVERY OF SIRNA - The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The present invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject. | 2009-03-05 |
20090060988 | Nell-1 enhanced bone mineralization - The present invention provides Nell-1 genes and gene products and pharmaceutical compositions comprising the same that promote bone mineralization and osteoblast differentiation. The Nell-1 genes and gene products also represent targets for screening for modulators of bone mineralization and osteoblast differentiation. In addition, Nell-1-associated compounds and compositions can be used to increase bone density and facilitate repair of bone fractures. | 2009-03-05 |
20090060989 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY - The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable. | 2009-03-05 |
20090060990 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY - The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDS) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable. | 2009-03-05 |
20090060991 | GLUTATHIONE BASED DELIVERY SYSTEM - A delivery system. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative. | 2009-03-05 |